MSCLF Message Board Post 9833642 | iCo Therapeutics
home / stock / msclf / msclf message board
tdageforde
(investorshub)
Posted on: Apr/17/2020 12:23:05
Source: investorshub
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155080690
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo
News, Short Squeeze, Breakout and More Instantly...
iCo Therapeutics Company Name:
MSCLF Stock Symbol:
Market:
-
Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSC...
-
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“ Satellos ” or the “ Company ”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of...
-
- Conducted preclinical toxicology studies and GMP manufacturing of SAT-3247 - On track to initiate Phase 1 first-in-human clinical trials mid-2024 - Cash balance of $33.2 million at March 31, 2024 - Invited to present at PPMD 30 th annual conference to be held J...